Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 17/20 | 0.47 |
| ▸ | CCND1 | P24385 | 17/20 | 0.47 |
| ▸ | CCND2 | P30279 | 13/20 | 0.47 |
| ▸ | CCND3 | P30281 | 13/20 | 0.47 |
| ▸ | CCNA2 | P20248 | 10/20 | 0.46 |
| ▸ | CDK2 | P24941 | 10/20 | 0.46 |
| ▸ | CCNA1 | P78396 | 6/20 | 0.46 |
| ▸ | CCNE2 | O96020 | 4/20 | 0.46 |
| ▸ | CCNE1 | P24864 | 4/20 | 0.46 |
| ▸ | CCNB2 | O95067 | 3/20 | 0.46 |
| ▸ | CDK1 | P06493 | 3/20 | 0.46 |
| ▸ | CCNB1 | P14635 | 3/20 | 0.46 |
| ▸ | CCNB3 | Q8WWL7 | 3/20 | 0.46 |
| ▸ | FGFR1 | P11362 | 7/20 | 0.46 |
| ▸ | FGFR2 | P21802 | 7/20 | 0.46 |
| ▸ | FGFR4 | P22455 | 7/20 | 0.46 |
| ▸ | FGFR3 | P22607 | 7/20 | 0.46 |
| ▸ | WEE1 | P30291 | 1/20 | 0.45 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.45 |
| ▸ | PAK1 | Q13153 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4225865 | 0.92 | WEE1 (0.54) | CDK4CCND1CCND2CCND3CCNA2 | |
| SCHEMBL4216668 | 0.91 | WEE1 (0.47) | CDK4CCND1CCND2CCND3CCNA2 | |
| SCHEMBL4634869 | 0.88 | WEE1 (0.45) | CDK4CCND1CCND2CCND3CDK2 | |
| SCHEMBL14306579 | 0.87 | CDK4 (0.46) | CDK4CCND1CCND2CCND3CCNA2 | |
| SCHEMBL3341919 | 0.85 | CDK4 (0.62) | CDK4CCND1CCND2CCND3CCNA2 | |
| Hydrochloric Acid SCHEMBL3344416 | 0.85 | CDK4 (0.62) | CDK4CCND1CCND2CCND3CCNA2 | |
| SCHEMBL14300938 | 0.84 | PIK3CD (0.58) | CDK4CCND1CCND2CCND3CCNA2 | |
| SCHEMBL4232772 | 0.84 | CCND3 (0.51) | CDK4CCND1CCND2CCND3CCNA2 | |
| SCHEMBL189897 | 0.83 | KDM4E (0.57) | CDK4CCND1CCND2CCND3CCNA2 | |
| SCHEMBL3339620 | 0.79 | CDK4 (0.55) | CDK4CCND1CCND2CCND3CCNA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1931670-B1 | PYRIDOPYRIMIDINONE INHIBITORS OF PI3K | EXELIXIS INC (US) | 2012-09-12 | — | — | EP | claimed |
| US-8247408-B2 | Pyridopyrimidinone inhibitors of PI3Kα for the treatment of cancer | EXELIXIS, INC. (US) | 2012-08-21 | — | — | US | claimed |
| US-20090062274-A1 | Pyridopyrimidinone inhibitors of pi3kalpha | EXELIXIS, INC (US) | 2009-03-05 | — | — | US | claimed |
| EP-1931670-A1 | PYRIDOPYRIMIDINONE INHIBITORS OF PI3K | Exelixis, Inc. (US) | 2008-06-18 | — | — | EP | claimed |
| WO-2007044698-A1 | PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kα | EXELIXIS, INC. (US) | 2007-04-19 | — | — | WO | claimed |
| EP-1931670-B1 | PYRIDOPYRIMIDINONE INHIBITORS OF PI3K | EXELIXIS INC (US) | 2012-09-12 | — | — | EP | disclosed |
| EP-1931670-B1 | PYRIDOPYRIMIDINONE INHIBITORS OF PI3K | EXELIXIS INC (US) | 2012-09-12 | — | — | EP | disclosed |
| US-8247408-B2 | Pyridopyrimidinone inhibitors of PI3Kα for the treatment of cancer | EXELIXIS, INC. (US) | 2012-08-21 | — | — | US | disclosed |
| US-8247408-B2 | Pyridopyrimidinone inhibitors of PI3Kα for the treatment of cancer | EXELIXIS, INC. (US) | 2012-08-21 | — | — | US | disclosed |
| US-8247408-B2 | Pyridopyrimidinone inhibitors of PI3Kα for the treatment of cancer | EXELIXIS, INC. (US) | 2012-08-21 | — | — | US | disclosed |
| US-20090062274-A1 | Pyridopyrimidinone inhibitors of pi3kalpha | EXELIXIS, INC (US) | 2009-03-05 | — | — | US | disclosed |
| US-20090062274-A1 | Pyridopyrimidinone inhibitors of pi3kalpha | EXELIXIS, INC (US) | 2009-03-05 | — | — | US | disclosed |
| US-20090062274-A1 | Pyridopyrimidinone inhibitors of pi3kalpha | EXELIXIS, INC (US) | 2009-03-05 | — | — | US | disclosed |
| EP-1931670-A1 | PYRIDOPYRIMIDINONE INHIBITORS OF PI3K | Exelixis, Inc. (US) | 2008-06-18 | — | — | EP | disclosed |
| WO-2007044698-A1 | PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kα | EXELIXIS, INC. (US) | 2007-04-19 | — | — | WO | disclosed |
| WO-2007044698-A1 | PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kα | EXELIXIS, INC. (US) | 2007-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062274-A1 | Pyridopyrimidinone inhibitors of pi3kalpha | PIK3CA, PIK3CD, PIK3CB | CDK4 265/4885CCND1 805/4885CCND2 1449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.